BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2014 4:06:00 PM | Browse: 1018 | Download: 1037
Publication Name World Journal of Gastroenterology
Manuscript ID 6743
Country/Territory Japan
Received
2013-10-28 11:31
Peer-Review Started
2013-10-29 10:23
To Make the First Decision
2013-12-04 09:22
Return for Revision
2013-12-05 19:09
Revised
2013-12-20 18:02
Second Decision
2014-02-20 09:04
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-02-20 09:33
Articles in Press
2014-05-23 11:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-05-26 14:07
Publish the Manuscript Online
2014-07-26 13:36
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Topic Highlights
Article Title Therapeutic applications of curcumin for patients with pancreatic cancer
Manuscript Source Invited Manuscript
All Author List Masashi Kanai
Funding Agency and Grant Number
Corresponding Author Masashi Kanai, MD, PhD, Department of Clinical Oncology and Pharmacogenomics, Graduate School of Medicine, Kyoto University Kyoto, Japan Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. kanai@kuhp.kyoto-u.ac.jp
Key Words Curcumin; Pancreatic cancer; Nuclear factor-kappa B; Bioavailability; THERACURMIN
Core Tip A growing body of evidence supports the idea that curcumin is a promising anticancer drug. Curcumin has anticancer effects, both alone and in combination with other anticancer drugs, through the modulation of a variety of molecular targets in preclinical models. However, the poor bioavailability of curcumin has been the major challenge to its clinical application. This problem has been overcome by the development of highly bioavailable forms of curcumin (THERACURMIN?), and higher plasma curcumin levels can now be achieved without increased toxicity. Further clinical trials will be necessary to test the therapeutic applications of this promising agent in patients with pancreatic cancer.
Publish Date 2014-07-26 13:36
Citation Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J Gastroenterol 2014; 20(28): 9384-9391
URL http://www.wjgnet.com/1007-9327/full/v20/i28/9384.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i28.9384
Full Article (PDF) WJG-20-9384.pdf
Full Article (Word) WJG-20-9384.doc
Manuscript File 6743-Review.doc
Answering Reviewers 6743-Answering reviewers.pdf
Copyright License Agreement 6743-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 6743-Language certificate.pdf
Peer-review Report 6743-Peer reviewer(s).pdf
Scientific Editor Work List 6743-Scientific editor work list.doc